Sanofi Mitigates Viscosupplement Sales Losses in 2Q19


Sanofi continues to correct course on its orthobiologics business, with a -5.4% revenue decline in 2Q19 after sustaining an almost -20% decline in 2018.


Quarterly Highlights

Continued struggles in the U.S. were offset somewhat by high-single-digit growth in ex-U.S. markets.
Sanofi seems to have stabilized...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us